Greenwich LifeSciences (GLSI) News Today $9.99 +0.01 (+0.10%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$10.02 +0.04 (+0.35%) As of 05/2/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases $35,568.00 in StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 3,600 shares of the stock in a transaction on Friday, April 25th. The stock was purchased at an average cost of $9.88 per share, with a total value of $35,568.00. Following the purchase, the chief executive officer now directly owns 5,570,602 shares of the company's stock, valued at approximately $55,037,547.76. This represents a 0.06 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.May 1 at 9:24 AM | marketbeat.comSnehal Patel Buys 3,600 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) StockApril 30, 2025 | insidertrades.comResearch Analysts Set Expectations for GLSI Q1 EarningsGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Research analysts at HC Wainwright reduced their Q1 2025 EPS estimates for shares of Greenwich LifeSciences in a research note issued to investors on Monday, April 21st. HC Wainwright analyst Y. Chen now anticipates that the company willApril 25, 2025 | marketbeat.comHC Wainwright Issues Negative Outlook for GLSI EarningsApril 25, 2025 | americanbankingnews.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Buys $48,492.00 in StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 5,400 shares of the company's stock in a transaction dated Thursday, April 17th. The stock was bought at an average cost of $8.98 per share, for a total transaction of $48,492.00. Following the completion of the transaction, the chief executive officer now directly owns 5,567,002 shares of the company's stock, valued at approximately $49,991,677.96. This trade represents a 0.10 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.April 24, 2025 | marketbeat.comHC Wainwright Boosts Greenwich LifeSciences (NASDAQ:GLSI) Price Target to $39.00HC Wainwright increased their price objective on Greenwich LifeSciences from $38.00 to $39.00 and gave the stock a "buy" rating in a report on Monday.April 23, 2025 | marketbeat.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Purchases 5,400 SharesApril 23, 2025 | insidertrades.comGreenwich LifeSciences price target raised to $39 from $38 at H.C. WainwrightApril 22, 2025 | markets.businessinsider.comGreenwich LifeSciences (NASDAQ:GLSI) Releases Earnings ResultsGreenwich LifeSciences (NASDAQ:GLSI - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.40).April 17, 2025 | marketbeat.comGreenwich LifeSciences (GLSI) Expected to Announce Earnings on MondayGreenwich LifeSciences (NASDAQ:GLSI) will be releasing earnings before the market opens on Monday, April 21, Financial Modeling Prep reports.April 15, 2025 | marketbeat.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires $32,760.00 in StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 3,600 shares of the firm's stock in a transaction that occurred on Monday, April 7th. The stock was bought at an average price of $9.10 per share, for a total transaction of $32,760.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,561,602 shares in the company, valued at approximately $50,610,578.20. The trade was a 0.06 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.April 10, 2025 | marketbeat.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires $48,015.00 in StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel purchased 5,500 shares of the firm's stock in a transaction that occurred on Friday, April 4th. The shares were bought at an average price of $8.73 per share, for a total transaction of $48,015.00. Following the acquisition, the chief executive officer now directly owns 5,558,002 shares in the company, valued at $48,521,357.46. This trade represents a 0.10 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.April 9, 2025 | marketbeat.comInsider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases 3,600 Shares of StockApril 9, 2025 | insidertrades.comSnehal Patel Acquires 5,500 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) StockApril 8, 2025 | insidertrades.comGreenwich LifeSciences Provides Global Update on FLAMINGO-01April 3, 2025 | globenewswire.comGreenwich LifeSciences announces ‘positive’ data from FLAMINGO-01 trialApril 3, 2025 | markets.businessinsider.comGreenwich Life rises on data from late-stage trial for breast cancer vaccineApril 2, 2025 | msn.comGreenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical TrialApril 2, 2025 | globenewswire.comGreenwich LifeSciences (NASDAQ:GLSI) Trading Down 6.7% - Here's What HappenedGreenwich LifeSciences (NASDAQ:GLSI) Shares Down 6.7% - Here's WhyApril 2, 2025 | marketbeat.comGreenwich LifeSciences Delays Yearly Report FilingMarch 31, 2025 | tipranks.comGreenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026March 27, 2025 | globenewswire.comGreenwich LifeSciences provides update on FLAMINGO-01 trialMarch 17, 2025 | markets.businessinsider.comGreenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01March 17, 2025 | globenewswire.comGreenwich LifeSciences (NASDAQ:GLSI) Trading Down 4% - Should You Sell?Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 4% - Here's What HappenedMarch 12, 2025 | marketbeat.com55% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is owned by insiders, and they've been buying recentlyMarch 5, 2025 | finance.yahoo.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) Sees Significant Growth in Short InterestGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 644,000 shares, an increase of 5.1% from the January 15th total of 612,700 shares. Based on an average trading volume of 33,700 shares, the short-interest ratio is currently 19.1 days. Currently, 10.9% of the shares of the stock are sold short.February 19, 2025 | marketbeat.comFY2024 Earnings Estimate for GLSI Issued By HC WainwrightGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Investment analysts at HC Wainwright boosted their FY2024 earnings estimates for shares of Greenwich LifeSciences in a report released on Tuesday, February 11th. HC Wainwright analyst Y. Chen now expects that the company will post earningFebruary 15, 2025 | marketbeat.comGreenwich LifeSciences (NASDAQ:GLSI) Given "Buy" Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $38.00 price target on shares of Greenwich LifeSciences in a research report on Tuesday.February 11, 2025 | marketbeat.comGreenwich LifeSciences reports progress in FLAMINGO-01 trialFebruary 10, 2025 | msn.comGreenwich LifeSciences provides update on FLAMINGO-01 open label HLA dataFebruary 10, 2025 | markets.businessinsider.comGreenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01February 10, 2025 | globenewswire.comGreenwich LifeSciences: Long Time To Results, Little Cash, Hard To RecommendFebruary 8, 2025 | seekingalpha.comEMA approves addition of sites to Greenwich LifeSciences’ breast cancer trialJanuary 30, 2025 | finance.yahoo.comGreenwich LifeSciences expands FLAMINGO-01 clinical trial into EuropeJanuary 29, 2025 | markets.businessinsider.comGreenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in EuropeJanuary 29, 2025 | globenewswire.comGreenwich LifeSciences announces activation of Phase 3 trial in PolandJanuary 27, 2025 | markets.businessinsider.comGreenwich LifeSciences Announces Activation of Flamingo-01 in PolandJanuary 27, 2025 | globenewswire.comGreenwich LifeSciences Adds Harvard And Johns Hopkins To FLAMINGO-01January 23, 2025 | markets.businessinsider.comGreenwich LifeSciences provides update on commercial manufacturing of GP2January 23, 2025 | markets.businessinsider.comGreenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01January 23, 2025 | globenewswire.comGreenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Commercial ManufacturingJanuary 22, 2025 | finanznachrichten.deGreenwich LifeSciences gains after GP2 commercial manufacturing updateJanuary 22, 2025 | msn.comGreenwich LifeSciences Provides Update on Commercial ManufacturingJanuary 22, 2025 | globenewswire.comGlancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)January 17, 2025 | businesswire.comGreenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01January 14, 2025 | globenewswire.comInsider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases 2,500 Shares of StockJanuary 14, 2025 | insidertrades.comGreenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into FranceJanuary 13, 2025 | markets.businessinsider.comInsider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Buys 2,500 Shares of StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 2,500 shares of the stock in a transaction dated Friday, January 10th. The shares were purchased at an average price of $12.51 per share, for a total transaction of $31,275.00. Following the completion of the purchase, the chief executive officer now directly owns 5,552,502 shares in the company, valued at $69,461,800.02. The trade was a 0.05 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.January 13, 2025 | marketbeat.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Buys 1,800 SharesJanuary 9, 2025 | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Acquires 1,800 SharesGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 1,800 shares of the company's stock in a transaction that occurred on Tuesday, January 7th. The stock was purchased at an average cost of $13.75 per share, for a total transaction of $24,750.00. Following the transaction, the chief executive officer now owns 5,550,002 shares in the company, valued at $76,312,527.50. The trade was a 0.03 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.January 8, 2025 | marketbeat.com Get Greenwich LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address GLSI Media Mentions By Week GLSI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLSI News Sentiment▼1.680.73▲Average Medical News Sentiment GLSI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLSI Articles This Week▼31▲GLSI Articles Average Week Get Greenwich LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SION News Today KURA News Today OPT News Today PRTA News Today URGN News Today STOK News Today MRVI News Today VERV News Today GHRS News Today MNMD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLSI) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
